| [1] |
Garcia-Carbonero R,Carnero A,Paz-Ares L.Inhibition of HSP90 molecular chaperones:moving into the clinic[J].Lancet Oncol,2013,14(9):358-369.
|
| [2] |
Rajan A, Kelly RJ, Trepel JB, et al. A phase I study of PF-04929113(SNX-5422),an orally bioavailable heat shock protein 90 inhibitor,in patients with refractory solid tumor malignancies and lymphomas[J].Clin Cancer Res,2011,17(21):6831-6839.
|
| [3] |
Jhaveri K, Taldone T, Modi S, et al. Advances in the clinical development of heat shock protein 90(Hsp90)inhibitors in cancers[J].Biochim Biophys Acta,2012,1823(3):742-755.
|
| [4] |
Joo JH,Dorsey FC,Joshi A,et al.Hsp90-Cdc37 chaperone complex regulates Ulk1-and Atg13-mediated mitophagy[J].Mol Cell,2011,43(4):572-585.
|
| [5] |
Ota A,Wang Y.Cdc37/Hsp90 protein-mediated regulation of IRE1alpha protein activity in endoplasmic reticulum stress response and insulin synthesis in INS-1 cells[J].J Biol Chem,2012,287(9):6266-6274.
|
| [6] |
Erazo T, Moreno A, Ruiz-Babot G, et al. Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5(ERK5)nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex[J].Mol Cell Biol,2013,33(8):1671-1686.
|
| [7] |
Wang Y,Xu W,Zhou D,et al.Coordinated regulation of serum-and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex[J].J Biol Chem,2014,289(8):4815-4826.
|
| [8] |
Sreeramulu S,Jonker HR,Langer T,et al.The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy[J].J Biol Chem,2009,284(6):3885-3896.
|
| [9] |
Hieronymus H,Lamb J,Ross KN,et al.Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators[J].Cancer Cell,2006,10(4):321-330.
|
| [10] |
Zhang T,Hamza A,Cao X,et al.A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells[J].Mol Cancer Ther,2008,7(1):162-170.
|
| [11] |
Zhang T,Li Y,Yu Y,et al.Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction[J].J Biol Chem,2009,284(51):35381-3539.
|
| [12] |
Sreeramulu S,Gande SL,Gobel M,et al.Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37,a kinome chaperone-cochaperone,by triterpene celastrol[J].Angew Chem Int Ed Engl,2009,48(32):5853-5855.
|
| [13] |
Yu Y,Hamza A,Zhang T,et al.Withaferin A targets heat shock protein 90 in pancreatic cancer cells[J].Biochem Pharmacol,2010,79(4):542-551.
|
| [14] |
Gu M,Yu Y,Gunaherath GM,et al.Structure-activity relationship(SAR)of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells[J].Invest New Drugs,2014,32(1):68-74.
|
| [15] |
Grover A,Shandilya A,Agrawal V,et al.Hsp90/Cdc37 chaperone/co-chaperone complex,a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A[J].BMC Bioinformatics, 2011,12(suppl 1):S30.
|
| [16] |
Wei H,Wei J,Hui-ling F,et al.Structure identification and anti-tumor activity research of FW-04-806[J].Chin J Antibiot(中国抗生素杂志),2011,7(36):874-877.
|
| [17] |
Huang W,Ye M,Zhang LR,et al.FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation[J].Mol Cancer,2014,13:150-163.
|
| [18] |
Clarke JD,Dashwood RH,Ho E.Multi-targeted prevention of cancer by sulforaphane[J].Cancer Lett,2008,269(2):291-304.
|
| [19] |
Rausch V,Liu L,Kallifatidis G,et al.Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics[J].Cancer Res,2010,70(12):5004-5013.
|
| [20] |
Lin LC,Yeh CT,Kuo CC,et al.Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/beta-catenin function[J].J Agric Food Chem,2012,60(28):7031-7039.
|
| [21] |
Gibbs A,Schwartzman J,Deng V,et al.Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6[J].Proc Natl Acad Sci U S A,2009,106(39):16663-16668.
|
| [22] |
Li Y,Karagoz GE,Seo YH,et al.Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37)complex and direct interactions with amino acids residues of Hsp90[J].J Nutr Biochem,2012,23(12):1617-1626.
|
| [23] |
Miyata Y. CK2: the kinase controlling the Hsp90 chaperone machinery[J].Cell Mol Life Sci,2009,66(11/12):1840-1849.
|
| [24] |
Dey B,Lightbody JJ,Boschelli F.CDC37 is required for p60v-src activity in yeast[J].Mol Biol Cell,1996,7(9):1405-1417.
|
| [25] |
Bandhakavi S,McCann RO,Hanna DE,et al.A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases[J].J Biol Chem,2003,278(5):2829-2836.
|
| [26] |
Abbas-Terki T,Donze O,Picard D.The molecular chaperone Cdc37 is required for Ste11 function and pheromone-induced cell cycle arrest[J].FEBS Lett,2000,467(1):111-116.
|
| [27] |
Lolli G,Cozza G,Mazzorana M,et al.Inhibition of protein kinase CK2 by flavonoids and tyrphostins.A structural insight[J].Biochemistry,2012,51(31):6097-6107.
|
| [28] |
Zhao M,Ma J,Zhu HY,et al.Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2,Cdc37 and Hsp90[J].Mol Cancer,2011,10(4):104-118.
|
| [29] |
He J,Niu X,Hu C,et al.Expression and purification of recombinant NRL-Hsp90alpha and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening[J].Protein Expr Purif,2013,92(1):119-127.
|
下载:
